SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR Annual Meeting

SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR Annual Meeting DUBLIN, Calif.--(BUSINESS WIRE)--Apr. 13, 2009-- SuperGen Inc., (NASDAQ:SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that multiple abstracts have been accepted for oral and poster presentations at the 100 th Annual Meeting of the American Association for Cancer Research (AACR), which will take place April 18-22 in Denver, Colorado. An oral presentation by Dr. Sanjeev Redkar will highlight SuperGen ’s PIM Kinase Inhibitor, SGI-1776, and the strategies SuperGen employed in the discovery and optimization of its potency and selectivity against PIM kinases as novel cancer therapeutic targets. The poster presentations will focus on data concerning many of SuperGen ’s current oncology programs, including the lead clinical compound, MP -470, and its ability to suppress the repair of double stranded DNA breaks following treatment with DNA-damaging agents. The discovery and characterization in pre -clinical cancer models of a new series of inhibitors of the non -receptor tyrosine kinase Etk/Bmx will also be presented. SuperGen’s schedule of presentations is as follows: About SuperGen Based in Dublin, California, SuperGen is a pharmaceutical company dedicated to the discovery and development of novel cancer therapies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com. Forward -Looking Statements This news release contains certain "forward -looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward -looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, our ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Date   Time (PDT)   Abstract # and Title Monday, April 20  2:25 pm - 2:40 pm (oral presentation)   #2013 – Discovery of SGI-1776, a potent and selective PIM -1 kinase inhibitor Tuesday, April 21   8 a.m. – noon  #3725 - Identifying sensitizers of aurora kinase inhibitors by high -throughput siRNA screening Tuesday, April 21   8 a.m. – noon  #3745 – Targeting Etk/Bmx kinase with small molecule inhibitors Tuesday April 21   8 a.m. – noon #3728 - MP470, a small molecule tyrosine kinase inhibitor, induces apoptosis in multiple myeloma cells Tuesday, April 21   8 a.m. – noon  #3729 – MP-470, a Rad51 suppressor and multiple TK inhibitor, retards growth of primary human glioblastoma multiforme (GBM) cells and synergizes effect of Temozolomide ex vivo Tuesday, April 21   8 a.m. – noon  #3743 - SGI-1776: A novel PIM kinase inhibitor with potent preclinical activity against Acute Myeloid Leukemia (AML) Exchange Commission including its most recently filed Form 10 -Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results. Source: SuperGen Inc. SuperGen, Inc. Timothy L. Enns, 925-560-2810 SVP, Corporate Communications & Business Development [email protected] Susanna Chau, 925 -560-2845 Investor Relations Manager [email protected]

The release as fetched from its publisher. astx.com ↗